Adenomyosis — Body Handbook

Healthcare · §596

Adenomyosis

If your periods soak through a pad in an hour, leave you doubled over with cramps, or make work and parenting feel optional that week — you may not be "bad at periods." You may have adenomyosis: a condition where the tissue that lines the uterus burrows into the muscle wall around it, turning a normal organ into a heavier, more painful, more bled-on one. It affects roughly one in five women walking into a gynaecology clinic, and the average diagnostic delay runs years. The good news is the treatments work: a hormonal IUD, a daily progestin pill, or a uterus-sparing procedure can reset the baseline within a few months.

Know · As-needed Evidence Moderate Chapter Healthcare

If you have it and don't know — the version of you that schedules around her period, hoards painkillers, and runs low on iron is a version that lifts when treated. A levonorgestrel IUD cuts menstrual bleeding by 70 to 90 percent and dulls the cramping within a few cycles; if that doesn't suit, daily dienogest does similar work on the pain. The catch is recognition: most clinicians aren't looking for it unless you make them, and a transvaginal ultrasound from someone who reads them well is usually the first useful step. Once treated, the everyday weight of "period week" stops being the planning constraint it was.

The uterus has two layers that matter here: a thin inner lining (the endometrium) that sheds every month, and a thick muscle wall around it (the myometrium) that contracts during periods and labour. In adenomyosis, pockets of the lining have pushed down into the muscle wall and set up shop. They don't belong there, but they still respond to the same monthly hormone cycle — swelling, bleeding, and shedding inside the muscle every cycle, with nowhere for the blood to go.

The muscle around those pockets reacts the way muscle reacts to a foreign irritant. It thickens, scars, and gets inflamed, which is why the uterus itself often grows larger and feels boggy on examination. The trapped bleeding triggers a flood of prostaglandins — the same chemicals behind ordinary cramps, but at much higher concentrations — which crank up muscle contractions and pain signalling at the same time Vannuccini et al. 2017. The heavier bleeding has two sources: a bigger uterine cavity to shed from, and fragile new blood vessels growing through the affected muscle that bleed more readily.

Two other knock-on effects matter. First, the muscle wall's normal wave-like contractions get scrambled — those waves are what move sperm toward the egg and an early embryo toward implantation, so when they're disrupted, fertility takes a hit Vercellini et al. 2014. Second, the lining itself becomes a worse place to implant: receptivity markers are off, inflammation runs high, and the tissue resists progesterone signalling that's supposed to prepare it for pregnancy Younes & Tulandi 2017.

How common, and how it gets found

For decades adenomyosis was a "diagnosis after the fact" — pathologists found it in uteruses removed for other reasons. That made it look like a rare condition of older women heading into hysterectomy. Better ultrasound changed the picture. In a 985-woman prospective study at a London gynaecology clinic, scanning unselected patients turned up adenomyosis in about one in five — strongly linked to age, prior pregnancies, and the presence of endometriosis Naftalin et al. 2012. Roughly a third of women with it have no symptoms at all; the rest run the gamut from "noticeably heavier periods" to "barely functional one week a month" Loring et al. 2022.

Imaging is the practical way in. A transvaginal ultrasound from a sonographer who knows what to look for catches roughly three out of four cases, with very few false alarms Champaneria et al. 2010. The features have been standardised — pockets of fluid inside the muscle, bright spots, a globular uterine shape, asymmetric thickening of the muscle wall, an irregular border between lining and muscle Van den Bosch et al. 2019 Harmsen et al. 2022. MRI is the tiebreaker when the ultrasound is unclear or surgery is being planned; the key measurement is the thickness of the junctional zone — the muscle just under the lining — at 12 mm or more on T2-weighted images.

What it costs to leave it alone

Untreated, the months look the same as they have for years — except they're stealing more each year. The week of your period stops being a week and starts being five days of pre-cramping, four days of hard bleeding with night-time pad changes, and a recovery weekend. Hours at work get marked down to "had to leave early," and your colleagues stop asking. You buy iron tablets every other month because the lab said you were low again — your hair sheds more in the shower, you nap on weekends, the stairs feel longer than they used to.

The bigger costs land on a slower timer. Heavy bleeding cycle after cycle drains iron faster than diet replaces it; iron-deficiency anaemia from menstrual loss is markedly more common in adenomyosis than in matched controls, and it pulls focus, energy, and exercise tolerance down with it Loring et al. 2022. If you're trying to get pregnant, the picture sharpens fast: IVF cycles produce roughly a third fewer clinical pregnancies in women with adenomyosis, and the miscarriage rate runs about two to three times higher Younes & Tulandi 2017 Vercellini et al. 2014. Pregnancies that do hold are more likely to run into preeclampsia, preterm birth, growth restriction, and placental problems — roughly double the risk on most endpoints Harada et al. 2022 Mochimaru et al. 2017.

The social damage is the part nobody charts. A friend stops inviting you to the Saturday hike because you keep cancelling. Your partner learns the calendar. You miss your kid's school thing. Ten years of "I'm fine, just a bad period" trades a real version of your week — every week — for a managed one.

What actually works

Treatment is staged: cheap and reversible first, more involved only if that doesn't hold. The right ladder depends on what bothers you most (bleeding vs pain), whether you want to get pregnant soon, and whether you've finished having kids.

First line: hormonal control of the cycle

The levonorgestrel intrauterine system — a small T-shaped device a clinician places in the uterus during an office visit — is the workhorse. It releases a low dose of progestin locally for five to seven years, thinning the lining and turning down the monthly bleed. Menstrual blood loss drops by 70 to 90 percent, cramping eases, and many users stop having periods altogether after the first few months Singh et al. 2023 Loring et al. 2022. Insertion is uncomfortable for ten minutes and the first few cycles can be irregular. After that, it's a set-and-forget option.

If an IUD isn't an option or hasn't worked, dienogest — a daily 2 mg progestin pill — is the alternative with the best modern evidence. A 2024 meta-analysis of 14 studies found dysmenorrhoea pain scores fell by roughly six points on a ten-point scale over six to twelve months, with continued benefit beyond two years Etrusco et al. 2024. A head-to-head trial against the levonorgestrel IUD showed broadly similar results for pain, with dienogest acting faster but causing more breakthrough bleeding Choudhury et al. 2024.

For milder cases, the basics still earn their place: NSAIDs (ibuprofen, naproxen) taken on a schedule starting the day before bleeding starts cut both flow and cramping. Tranexamic acid taken only on the heaviest days reduces blood loss by roughly a third to a half Bryant-Smith et al. 2018. Combined oral contraceptives help cycle control and pain but lag the IUD on heavy bleeding Lethaby et al. 2019.

Second line: procedures that spare the uterus

Uterine artery embolisation blocks the small arteries feeding the affected tissue through a catheter run from a wrist or groin vessel — no incisions, one to two days of recovery. A meta-analysis of 15 studies found symptom improvement in about 83% of patients short-term, with around 7% eventually needing a hysterectomy anyway over the next year or more de Bruijn et al. 2017. Effects on future fertility are uncertain — discuss carefully if pregnancy is still on the table.

High-intensity focused ultrasound (sometimes called MRgFUS) destroys the adenomyotic tissue with focused sound waves, no incisions. Results vary widely between centres; expect substantial improvement in cramping in most patients and partial shrinkage of the uterus. Availability is limited and costs are high Marques et al. 2020.

Third line: definitive surgery

Hysterectomy — removal of the uterus — is the only treatment that fully cures adenomyosis, because it removes the affected organ. It's the right call when the symptoms are dominant, conservative options have failed, and childbearing is finished. Modern laparoscopic and vaginal approaches mean a few days in hospital and a four-to-six-week recovery; the ovaries are usually left in place so menopause isn't forced early.

For women still trying to conceive who haven't responded to other options, adenomyomectomy — surgical removal of the adenomyotic tissue while keeping the uterus — is an option in specialised centres. Pregnancy rates afterwards run around 50% in published series, but the surgery is technically demanding and the operated uterus carries a higher risk of rupture during later pregnancy Liu et al. 2024.

If you're trying to get pregnant

Adenomyosis lowers IVF success rates roughly a third and roughly doubles miscarriage risk in standard cycles Younes & Tulandi 2017. Two to three months of GnRH agonist suppression before a frozen embryo transfer improves clinical pregnancy and live-birth rates in adenomyosis patients — increasingly the standard approach when adenomyosis is severe and IVF is on the table Younes & Tulandi 2017. Talk this through with a reproductive endocrinologist who treats adenomyosis often; outcomes depend heavily on operator experience.

What most guidance gets wrong

"It only affects women in their forties who've had kids." Older series said so because they only looked at hysterectomy specimens. With modern ultrasound, the condition turns up in nulliparous women in their twenties and even adolescents Bourdon et al. 2021. If your periods got worse over the last few years and a clinician tells you you're "too young" for adenomyosis, get a second read.
"Heavy painful periods are just genetics." Severe dysmenorrhoea — the kind that requires planning your week around it — is a medical signal, not a personality trait. The historic dismissal of menstrual pain is the single biggest reason diagnostic delay still runs years.
"Hysterectomy is the only real fix." True only for the small fraction who get there. The levonorgestrel IUD and dienogest together address the bulk of symptoms in most patients without removing anything Singh et al. 2023.
"It's the same thing as endometriosis." They're related and often coexist (around half the time), but they're different diseases — endometriosis sits outside the uterus, adenomyosis sits inside the uterine muscle. Treatments overlap; surgical strategies differ.

Where treatment goes sideways

Stopping the IUD because of the first three months. Irregular spotting is the rule, not a failure, for the first 8–12 weeks after insertion. The bleeding settles and most users end up with much lighter periods or none at all. The patients who quit at six weeks miss the benefit; the patients who wait to month four usually keep it.
Treating "fibroids" that are actually adenomyomas. Focal adenomyosis can look on imaging like a fibroid — a discrete lump in the muscle wall. The wrong call points the patient at a myomectomy that doesn't fix the symptoms, because the surrounding muscle is also diseased. A clinician familiar with MUSA criteria reads them apart Harmsen et al. 2022.
Skipping the iron workup. Years of heavy bleeding deplete iron stores far before the haemoglobin technically drops into the anaemic range. Ferritin is the right test; a "normal" haemoglobin without ferritin checked is incomplete. Replacement (oral or IV depending on severity) is what restores energy in parallel with controlling bleeding.
Assuming the procedure ends the story. Embolisation and HIFU both have a meaningful re-intervention rate over five to ten years; the literature reports hysterectomy needed in ~7% within a year or two after embolisation, with the share rising in longer follow-up de Bruijn et al. 2017 Liu et al. 2024. Knowing that going in keeps "the symptoms came back" from feeling like failure.
IVF without preparing the uterus. Going into a transfer cycle with active adenomyosis and no GnRH suppression gives the embryo a hostile lining to land on. Patients who do two to three months of pretreatment, then a frozen embryo transfer, get materially better odds Younes & Tulandi 2017.

When standard treatment isn't safe

Two cautions for fertility-seeking patients: embolisation's long-term fertility outcomes are still under-studied, and adenomyomectomy raises the risk of uterine rupture during later pregnancy. Both warrant a careful conversation with someone who treats adenomyosis specifically — not a generalist.

Red flags that need urgent evaluation rather than this article's protocol: bleeding heavy enough to cause faintness or shortness of breath; any postmenopausal bleeding; bleeding between periods that's new or unexplained; pregnancy desired and not achieving it after six to twelve months of trying. All of these need a clinician now, not a self-managed plan.

What changes if you treat it

Onset depends on the treatment. NSAIDs and tranexamic acid work the cycle you take them. The levonorgestrel IUD shows its main bleeding effect by month three and its full effect by month six; dienogest reaches steady-state pain control around the same window Etrusco et al. 2024. Embolisation is a one-time event with results stable by three to six months; hysterectomy is immediate.

The first month, you notice the small things. The drawer of overnight pads stops being a daily-use drawer. The painkiller bottle stays on the shelf where it belongs. You make it through a workday in week-two-of-the-month without watching the clock.

By month three to six, your iron starts to recover. You stop feeling like you need an afternoon nap by 3 pm. Your hair sheds normally in the shower again. The friend who had stopped inviting you to weekend things, because you kept cancelling, invites you to weekend things — and you go.

By year one, the weekly arithmetic of "what will I be able to do that week" is gone. You stop scheduling around your period because you don't need to. If pregnancy is the goal, IVF cycles after appropriate suppression run at substantially better odds than they would have, and the pregnancy itself — with closer monitoring for the obstetric risks adenomyosis brings — is more likely to make it to term Younes & Tulandi 2017 Harada et al. 2022.

Adjacent topics

Endometriosis — the close cousin that sits outside the uterus; coexists with adenomyosis about half the time.
Uterine fibroids — different muscle-wall pathology that often coexists; easy to confuse on imaging.
Iron-deficiency anaemia — the downstream condition many adenomyosis patients are quietly carrying.
IVF and assisted reproduction — relevant if the diagnosis came up during a fertility workup.
Chronic pelvic pain — broader workup when adenomyosis treatment doesn't fully resolve the pain.

Related in the handbook

Worsens / aggravates

— Months of heavy bleeding quietly drain your iron — that exhaustion may be the deficiency, not just cramps.

Helps

— A hormonal IUD cuts the bleeding 70-90% and dulls the pain — usually the first thing to try.
— Logging how heavy and how painful your periods really are gives the gynaecologist the pattern that points at adenomyosis.

— Heavy painful periods are the classic sign of adenomyosis hiding behind a 'normal' label.
— Adenomyosis and endometriosis often occur together and overlap in symptoms; both need imaging to sort out.
— Fibroids are the other muscle-wall cause of heavy painful periods, and the two frequently travel together.

Substance + claimed effects

Adenomyosis is a benign gynecological disorder defined by the presence of ectopic endometrial glands and stroma within the uterine myometrium, surrounded by hyperplastic and hypertrophic smooth muscle Vannuccini et al. 2017. It manifests as either diffuse (lesions involving >25% of the myometrium) or focal (adenomyomas — discrete nodular lesions) disease, per the MUSA classification system Van den Bosch et al. 2019 Harmsen et al. 2022. This entry covers the substance and its meaningful consequences: heavy menstrual bleeding (HMB), severe dysmenorrhea, chronic non-cyclic pelvic pain, uterine enlargement, iron-deficiency anemia, impaired fertility, adverse obstetric outcomes (preeclampsia, preterm birth, miscarriage, placental malposition), and the cascade of quality-of-life impacts that follow.

Evidence by addressing question

Mechanism

Two competing mechanistic theories dominate. The tissue injury and repair (TIAR) / invagination theory proposes that repeated micro-trauma at the endometrial–myometrial junction — from menstruation itself, parturition, cesarean section, dilation and curettage — induces local hyperestrogenism, which drives invagination of the endometrial basalis into the inner myometrium Vannuccini et al. 2017. The metaplasia theory proposes de novo origin from displaced embryonic Müllerian remnants or adult stem cells Vannuccini et al. 2017. Convergent molecular features include increased estrogen-receptor expression, local aromatase activity (driving intra-tissue estrogen synthesis), progesterone resistance, epithelial-to-mesenchymal transition (EMT) of endometrial cells, increased neoangiogenesis, fibrosis, and altered smooth-muscle architecture of the junctional zone Vannuccini et al. 2017 Bourdon et al. 2021.

Symptom pathophysiology. Heavy menstrual bleeding is driven by an enlarged endometrial surface area (uterine cavity distortion and increased volume), neoangiogenesis with fragile vessels in the affected myometrium, and impaired hemostasis. Dysmenorrhea reflects elevated prostaglandin (especially PGF2α) and pro-inflammatory cytokine production (IL-1β, IL-6, TNFα), uterine hypercontractility, and peripheral/central sensitization of nociceptors at the lesion site Vannuccini et al. 2017. Infertility mechanisms include impaired endometrial receptivity (dysregulated HOXA10 and implantation markers), abnormal uterine peristalsis disrupting sperm transport, junctional-zone thickening interfering with implantation, and a hostile pro-inflammatory uterine milieu Vercellini et al. 2014 Younes & Tulandi 2017.

Evidence

Prevalence. Historically estimated from hysterectomy specimens (likely overestimates) at 20–35%. The landmark Naftalin et al. prospective ultrasound study in a general gynecology clinic of 985 women found prevalence of 20.9% (95% CI 18.5–23.6%), with independent associations with age, gravidity, and pelvic endometriosis Naftalin et al. 2012. Adenomyosis coexists with endometriosis in 21–80% of cases and with leiomyomas in approximately 30% Brucker et al. 2014.

Diagnostic accuracy. The Champaneria systematic review pooled transvaginal ultrasound (TVUS) sensitivity at 72–82% and specificity at 81–85%; pelvic MRI sensitivity at 77% (95% CI 67–85%) and specificity at 89% (95% CI 84–92%) Champaneria et al. 2010. The MUSA criteria (revised by Delphi consensus 2022) standardize TVUS reporting using direct features (myometrial cysts, hyperechogenic islands, echogenic subendometrial lines/buds) and indirect features (globular uterus, asymmetric myometrial thickening, fan-shaped shadowing, translesional vascularity, irregular or interrupted junctional zone) Van den Bosch et al. 2019 Harmsen et al. 2022. MRI gold-standard finding is junctional zone thickness ≥12 mm on T2-weighted imaging.

Symptom impact. Up to one-third of patients are asymptomatic; the remainder report HMB (most common), severe dysmenorrhea, chronic pelvic pain, and bulk symptoms from enlarged uterus Loring et al. 2022. Iron-deficiency anemia rates are substantially elevated in adenomyosis cohorts versus controls.

Stakes

Fertility. Younes & Tulandi 2017 meta-analysis of IVF outcomes found reduced clinical pregnancy rate (OR 0.69; 95% CI 0.51–0.94), reduced implantation rate, and increased miscarriage rate (OR 2.17; 95% CI 1.25–3.79) in women with adenomyosis undergoing ART Younes & Tulandi 2017. Vercellini et al. 2014 reported clinical pregnancy rate per cycle in IVF was reduced by 28% in adenomyosis patients (RR 0.72) and miscarriage rate roughly doubled Vercellini et al. 2014.

Obstetric complications. Adenomyosis is associated with significantly increased risks of preterm birth (OR ~2), preeclampsia (OR up to 7.87 in one cohort; ~3 pooled), small-for-gestational-age infants, placental malposition, postpartum hemorrhage, second-trimester miscarriage, and cesarean delivery Harada et al. 2022 Mochimaru et al. 2017. Risk scales with uterine enlargement and is higher in diffuse than focal disease.

Protocol

First-line medical management: levonorgestrel-releasing intrauterine system (LNG-IUS, 52 mg) — reduces menstrual blood loss by 70–90%, reduces dysmenorrhea, and reduces uterine volume; durable for 5–7 years Singh et al. 2023 Loring et al. 2022. Dienogest 2 mg/day — meta-analysis of 14 studies showed VAS pain reduction of ~5.86 cm on a 10-cm scale; modest uterine volume reduction; main side effect is irregular bleeding Etrusco et al. 2024 Choudhury et al. 2024. Direct head-to-head RCT (Choudhury 2024) found comparable pain reduction; DNG showed faster onset at 3 months but more breakthrough bleeding. Combined oral contraceptives: useful for pain and cycle control but less effective for bleeding than LNG-IUS Lethaby et al. 2019. GnRH agonists: effective short-term but require add-back therapy due to hypoestrogenic side effects; useful as bridge to surgery or pre-IVF. NSAIDs and tranexamic acid: symptomatic, reduce bleeding 26–60% Bryant-Smith et al. 2018.

Procedural/surgical options. Uterine artery embolization (UAE): de Bruijn meta-analysis (15 studies) reported short-term symptom improvement in 83.1% of patients; long-term (>1 year) hysterectomy rate ~7.2%; significant improvement in quality of life and bleeding de Bruijn et al. 2017. High-intensity focused ultrasound (HIFU/MRgFUS): Marques et al. meta-analysis showed dysmenorrhea reduction in 25–100% and uterine volume reduction of 12–54% — highly variable; better ovarian-function preservation than UAE Marques et al. 2020. Adenomyomectomy (uterus-sparing surgery): pooled post-op pregnancy rates ~50% in fertility-seeking patients; reintervention rates substantial. Hysterectomy — definitive cure; appropriate when childbearing complete and conservative management fails Singh et al. 2023 Liu et al. 2024.

Fertility-focused management. Long-term GnRH agonist pretreatment (2–6 months) before frozen embryo transfer improves clinical pregnancy and live birth rates in adenomyosis patients undergoing IVF Younes & Tulandi 2017.

Risk factors / contraindications

Established risk factors: increasing age (peak diagnosis 40–50), multiparity, prior uterine surgery (cesarean section, D&C, myomectomy), tamoxifen use, and prior history of endometriosis or fibroids Loring et al. 2022. Mechanism contraindications for treatments: LNG-IUS — current breast cancer, undiagnosed bleeding; dienogest — known/suspected pregnancy, severe liver disease, hormone-dependent malignancy; GnRH agonists — pregnancy, prolonged use without add-back; UAE — contraindicated in active pelvic infection, pregnancy desire (relative — fertility data limited).

Misconceptions

Three common misperceptions: (1) "Adenomyosis only affects older women who have had children" — TVUS series document substantial prevalence in younger nulliparous women and adolescents Bourdon et al. 2021. (2) "Hysterectomy is the only treatment" — multiple effective uterus-sparing medical and procedural options exist. (3) "Heavy painful periods are just normal" — significant under-diagnosis persists; mean delay from symptom onset to diagnosis exceeds 5 years in some series.

Audience / population variability

Adenomyosis exclusively affects individuals with a uterus; the disease is hormonally driven and active during reproductive years, regressing after menopause. Risk and presentation vary substantially: younger patients (20–30s) increasingly recognized due to better imaging; perimenopausal patients dominate hysterectomy series. Coexisting endometriosis (21–80% overlap) modifies symptom profile and complicates fertility evaluation.

Practicalities

Initial workup: pelvic exam (may reveal globular tender uterus), CBC for anemia screening, TVUS as first-line imaging. MRI when sonography is equivocal or surgical planning needed. NSAIDs and tranexamic acid are available OTC or with low-cost prescription. LNG-IUS upfront cost is several hundred USD with insurance coverage common; provides 5–7 years of treatment. UAE costs are roughly $10,000–$20,000 (US); hysterectomy similar range. International availability of HIFU is limited.

Out-of-scope (pointers)

Endometriosis (often coexisting, distinct entity), uterine fibroids (often coexisting), heavy menstrual bleeding workup more broadly, iron-deficiency anemia management, IVF protocols.

The credibility range

Optimist case

Adenomyosis is a well-characterized, treatable condition with multiple effective therapeutic options. The LNG-IUS reduces bleeding by 70–90% and dysmenorrhea substantially, with durable effect at low cost — a transformative quality-of-life intervention for many patients. Dienogest is supported by multiple RCTs and meta-analyses with consistent pain reduction. Imaging diagnosis has matured (MUSA criteria, MRI thresholds), enabling non-invasive identification without surgical specimens. Uterus-sparing procedural options (UAE, HIFU) preserve fertility potential and offer durable symptom relief in most patients. Hysterectomy provides definitive cure when desired. Recognition is improving and diagnostic delay shrinking. For symptomatic patients, the trajectory from diagnosis to substantially improved quality of life is realistic and well-evidenced.

Skeptic case

The condition's definition remains contested — histologic depth-of-invasion criteria vary by pathologist, ultrasound criteria are still being standardized, and there is no universally accepted clinical diagnostic gold standard. Prevalence estimates range from 5% to 70% depending on cohort and method, suggesting we are still measuring different phenomena. No first-line treatment is curative short of hysterectomy; medical therapies require ongoing use and have meaningful side-effect burdens (breakthrough bleeding, mood effects from progestins, hypoestrogenic symptoms from GnRH agonists). UAE long-term durability is imperfect — ~7% hysterectomy rate within 1+ year. Fertility data on uterus-sparing procedures are limited and obstetric risks (uterine rupture, placental abnormalities) are real. Most RCT evidence is small and short-duration; the dienogest meta-analysis is heterogeneous; head-to-head trials between modalities are rare. Many findings derive from observational designs vulnerable to selection bias.

Author's call

Adenomyosis is real, common, and clinically meaningful — but the evidence base, while solid for symptom control, is moderate rather than airtight. The condition warrants evidence: 4 — multiple consistent observational cohorts, several reasonable-quality RCTs for medical management (dienogest, LNG-IUS), and clinical guideline endorsement (SOGC 2023, AAFP 2022) — short of a 5 because no Cochrane-level evidence base exists for definitive comparative treatment and prevalence figures remain method-dependent. Controversy is moderate (around 2): there's broad consensus the condition exists and warrants treatment, but field disagreement persists on diagnostic thresholds, optimal first-line therapy, and management in fertility-seeking patients.

Stakeholder + incentive map

Gynecologists / OB-GYNs — primary diagnosticians and treating clinicians; incentivized to identify and treat (both medically and surgically).
Interventional radiologists — promote UAE as uterus-sparing alternative; commercial interest in procedure volume.
Pharma — dienogest (Bayer) and other progestin manufacturers have commercial interest in adenomyosis-indication expansion; LNG-IUS (Mirena, Bayer) similarly.
Patient advocacy — organizations like the Adenomyosis Advice Association push for recognition, faster diagnosis, and research funding; address widespread under-diagnosis.
Surgical specialists — minimally-invasive gynecologic surgeons advocate for adenomyomectomy and laparoscopic techniques.
Counter-incentive — some clinicians historically dismissed dysmenorrhea and HMB as "normal" or psychosomatic; under-diagnosis remains a documented pattern, especially in younger and nulliparous patients.

Population variability

Age — peak diagnostic prevalence 35–50; increasing recognition in younger women (20–30s) due to better TVUS sensitivity; rare diagnosis in adolescents (but described).
Parity — risk increases with parity; nulliparous patients are still affected (~20% of confirmed cases in some series).
Prior surgery — D&C, cesarean section, myomectomy each increase risk via the TIAR mechanism.
Tamoxifen users — long-term tamoxifen treatment for breast cancer markedly elevates adenomyosis risk via increased estrogen exposure.
Endometriosis comorbidity — 21–80% overlap; presentation more severe and complex.
Ethnic/geographic data — limited; most prevalence studies in Western and East Asian populations; rural and low-resource setting data sparse.
Menopause — symptoms regress; lesions involute due to estrogen loss.

Knowledge gaps

No globally accepted clinical diagnostic gold standard short of histology; MUSA criteria reproducibility still under study.
True population prevalence remains uncertain — symptomatic vs asymptomatic ratio not well-quantified.
Head-to-head comparative effectiveness trials between LNG-IUS, dienogest, GnRH agonists, UAE, HIFU are sparse; QUESTA trial results (UAE vs hysterectomy) recently reported but not yet definitively settling the question.
Long-term obstetric safety of UAE and HIFU in subsequent pregnancies underpowered for rare events (uterine rupture, placenta accreta).
Mechanistic understanding of adenomyosis-associated infertility incomplete; whether the disease causes infertility or merely co-occurs with reduced fertility (via comorbid endometriosis, age) is debated.
Pathogenesis: definitive resolution of invagination vs metaplasia theories awaits longitudinal molecular data.
No prevention strategy beyond avoiding unnecessary uterine instrumentation.

Scope vs. brief. The brief named bleeding, pain, uterine size, fertility, and management — all covered. Coexistence with endometriosis surfaces repeatedly but is not given its own section here; endometriosis warrants its own entry (and the close-cousin framing in the misconceptions section makes the relationship clear without conflating the two).

Action call. Chose action: know rather than respond. The reader's job is recognising the symptom pattern, getting imaged, and entering a clinician's pathway — closer to condition literacy than to a specific protocol. Cadence is as-needed: once diagnosed and treated, the action isn't recurring.

Audience. Scoped female, ages 18–39 and 40–59. Omitted 60+ since adenomyosis regresses after menopause; the actionable population is reproductive-age and perimenopausal.

Rating difficulties. Most ratings are for treated adenomyosis rather than the natural history — the article frames treatment as the lever. energy: 3 and mood: 3 reflect the magnitude of symptom resolution in symptomatic patients (which is a substantial subset), not effects on asymptomatic patients. focus: 2 is the most uncertain — it's an indirect lift via anemia correction and pain relief rather than a direct cognitive effect; could be argued either 1 or 2. longevity: 1 reflects modest indirect mortality effects via obstetric complication prevention and anemia; not a longevity intervention proper. evidence: 4 rather than 5 because no Cochrane-level comparative effectiveness data exist for definitive treatment selection between LNG-IUS, dienogest, UAE, and other modalities — the QUESTA trial results are still settling.

Contraindications field. Left empty in meta because the closed vocabulary tokens (pregnancy, breastfeeding, etc.) apply to specific treatments rather than to the entry's primary action (recognition). The contraindications addressing section covers treatment-specific cautions where they actually apply.

Future-link candidates. An endometriosis entry (most natural sibling), an iron-deficiency anaemia entry (downstream of HMB), a heavy menstrual bleeding workup entry (if it doesn't already exist), and an IVF / assisted reproduction overview entry. The related meta field was not populated since I don't have visibility into which of these already exist as live entries.

Excluded with reason. Detailed surgical technique (adenomyomectomy variants, hysterectomy approaches) — operator-specific, not actionable for the reader. Specific MRI sequences and ultrasound calibration parameters — clinician-facing detail. Pathology grading and histologic depth-of-invasion criteria — academic, not load-bearing for the patient. Specific drug-drug interactions for dienogest and GnRH agonists — belongs in pharmacology resources, not a condition handbook.

Hard call: how much fertility content. Fertility could anchor its own entry. Chose to keep it as a major thread inside this article because the brief named fertility explicitly and because adenomyosis-specific fertility considerations (GnRH pretreatment before FET, the IVF success rate hit, obstetric risk profile) don't generalise from generic infertility content. Pulled it out as its own subsection in the protocol and threaded it through stakes and payoff rather than letting it dominate.